In the United States<unk>  is indicated for use in previously treated adults and adolescents (twelve years of age and older) with hemophilia A (congenital Factor VIII deficiency) for: (1) On-demand treatment and control of bleeding episodes ; (2) Perioperative management of bleeding; (3) Routine prophylaxis to reduce the frequency of bleeding episodes. In the European Union,<unk>  is indicated for the treatment and prophylaxis of bleeding in previously treated people twelve years of age and older with haemophilia A (congenital factor VIII deficiency).
Damoctocog alfa pegol
Efgartigimod alfa
Susoctocog alfa
Vonicog alfa
Efmoroctocog alfa
Ciltacabtagene autoleucel
Levomilnacipran
Brexucabtagene autoleucel